cancrum oris
Last edited 03/2022 and last reviewed 05/2022
Noma (cancrum oris)
- is a severely debilitating orofacial disease
- is a gangrenous infection that causes rapid, widespread orofacial destruction
- most frequently affects children between 2 and 5 years of age who live in low-income settings in Africa and Asia (2)
- the World Health Organization (WHO) estimates that 140,000 new cases of noma occur annually (2)
- affects malnourished children and mainly observed in tropical countries, particularly sub-Saharan Africa (3)
- was once frequently reported in Europe and North America, although as living conditions improved in these settings, noma has been eradicated (besides a few sporadic cases in immunocompromised individuals)
- leukaemic patients:
- often a terminal complicaton of the disease
- associated with the use of anti-inflammatory and immunosuppressive drugs
- a mortality rate of approximately 85% and a burden of disease calculated to be a loss of 1-10 million disability-adjusted life year (3)
- the World Health Organization (WHO) estimates that 140,000 new cases of noma occur annually (2)
- cause of noma is unknown, and noma is not contagious (1)
- main risk factors for noma include chronic malnutrition, a lack of access to healthcare (specifically immunizations), and comorbidities such as measles and human immunodeficiency virus (HIV)
- measles:
- especially in the malnourished, typically in children in tropical Africa
- cranium oris develops from an acute, ulcerative gingivitis
- main risk factors for noma include chronic malnutrition, a lack of access to healthcare (specifically immunizations), and comorbidities such as measles and human immunodeficiency virus (HIV)
- pathogenesis is a fast-spreading, noncontagious gangrenous infection occurring in the face, often preceded by acute necrotizing gingivitis, and stomatitis (3)
- rare microbiological studies suggest an opportunistic infection caused by an imbalance in normal intraoral microorganisms
- WHO classifies noma into stages: Stage 0: simple gingivitis, Stage 1: acute necrotizing gingivitis, Stage 2: oedema, Stage 3: gangrene, Stage 4: scarring, and Stage 5: sequelae
- reported mortality rate for untreated patients is 90% within weeks after the onset of first symptoms (1)
- treatment in the early acute stages with antibiotics, wound debridement, and nutritional support greatly reduces mortality and morbidity
- late treatment consists of surgical rehabilitation, which is often complex (3)
- survivors of the acute stages of noma face a lifetime of functional challenges such as difficulty eating and speaking
Reference:
- Farley E, Ariti C, Amirtharajah M, et al. Noma, a neglected disease: A viewpoint article. PLoS Negl Trop Dis. 2021;15(6):e0009437. Published 2021 Jun 17. doi:10.1371/journal.pntd.0009437
- World Health Organization (WHO). Noma is a severe disease It is treatable if detected and managed early. Republic of Congo: Brazzaville; 2016.
- Srour ML, Marck K, Baratti-Mayer D. Noma: Overview of a Neglected Disease and Human Rights Violation. Am J Trop Med Hyg. 2017;96(2):268-274. doi:10.4269/ajtmh.16-0718